natgillin/translations-raw huggingface dataset:
Netupitant or a pharmaceutically acceptable salt thereof, for use in treating nausea and vomiting for a period of five consecutive days in a patient in need thereof, said netupitant being administered in a therapeutically effective amount which is effective to treat nausea and vomiting during the acute and delayed phases of emesis, and which enters the systemic circulation, crosses the blood brain barrier and occupies at least 70% of NK1 receptors in the striatum seventy-two hours after said administration, wherein the following are administered: 
Netupitant ili njegova farmaceutski prihvatljiva sol, za uporabu u liječenju mučnine i povraćanja tokom razdoblja od pet uzastopnih dana kod pacijenta kod kojeg postoji potreba za tim, pri čemu se netupitant primjenjuje u terapeutski efikasnoj količini koja je efikasna za liječenje mučnine i povraćanja u toku akutnih i odloženih faza emezisa, i koja ulazi u sustavnu cirkulaciju, prolazi kroz krvno moždanu barijeru i zauzima najmanje 70% NK1receptora u strijatu sedamdeset i dva sata poslije navedene primjene, gdje su slijedeći primjenjeni:
on day one, a first dose of dexamethasone which is ineffective against nausea and vomiting when administered alone, but effective against nausea and vomiting when administered in combination with said netupitant, wherein said first dose comprises from 50 to 70% of a minimum effective dose when administered alone; and 
na dan jedan, prva doza deksametazona koja je neefikasna protiv mučnine i povraćanja kada je primjenjena pojedinačno, ali efikasna protiv mučnine i povraćanja kada je primjenjena u kombinaciji sa navedenim netupitantom, gdje navedena prva doza sadrži od 50 do 70% minimalne efikasne doze kada se primjenjuje pojedinačno; i
Netupitant for use according to claims 1-4, wherein said therapeutically effective amount of netupitant comprises from about 200 to about 400 mg. of netupitant or a pharmaceutically acceptable salt thereof, said therapeutically effective amount of 5-HT3 antagonist comprises from about 0.25 to about 0.75 mg of palonosetron or a pharmaceutically acceptable salt thereof, and said therapeutically minimum effective dose of dexamethasone when administered alone comprises from about 16 mg to about 20 mg of dexamethasone. 
Netupitant za uporabu prema patentnim zahtjevima 16-17, naznačen time što navedena terapeutski efikasna količina netupitanta sadrži od oko 200 do oko 400 mg netupitanta ili njegove farmaceutski prihvatljive soli, pri čemu navedena terapeutski efikasna količina 5-HT3 antagonista sadrži od oko 0.25 do oko 0.75 mg palonosetrona ili njegove farmaceutski prihvatljive soli, i navedena terapeutski minimalna efikasna doza deksametazona kada se primjenjuje pojedinačno također sadrži od oko 16 mg do oko 20 mg deksametazona.
if said patient is undergoing highly emetogenic chemotherapy, about 8 mg of dexamethasone are administered on days two, three and four. 
ako se navedeni pacijent podvrgava visoko emetogenoj kemoterapiji, oko 8 mg deksametazona je primjenjeno na dane dva, tri i četiri.
Netupitant for use according to claims 1-21, wherein said nausea and vomiting is induced by moderately or highly emetogenic chemotherapy. 
Netupitant za uporabu prema patentnim zahtjevima 1-21, naznačen time što je navedena mučnina i povraćanje inducirana/inducirano srednje ili visoko emetogenom kemoterapijom.
The combination for use according to claim 25 or 26, wherein about 300 mg. of netupitant as the free base, and about 0.56 mg. of palonosetron hydrochloride are orally administered. 
Kombinacija za uporabu prema patentnom zahtjevu 25 ili 26, naznačena time da se oko 300 mg netupitanta kao slobodna baza, i oko 0.56 mg palonosetron hidroklorida oralno primjenjuje.
wherein substituents for amide, sulfonamide, sulfonamido, and carbamate are at least one alkyl, substituted alkyl, alkenyl, substituted alkenyl, cycloalkyl, and substituted cycloalkyl; 
pri čemu su supstituenti za amid, sulfonamid, sulfonamido i karbamat barem jedan alkil, supstituirani alkil, alkenil, supstituirani alkenil, cikloalkil i supstituirani cikloalkil;
wherein substituents for cycloalkenyl and carbocyclic ring are alkyl, preferably lower alkyl, alkoxy, preferably lower alkoxy, nitro, monoalkylamino, preferably a lower alkylamino, dialkylamino, preferably a di[lower]alkylamino, cyano, halo, haloalkyl, preferably trifluoromethyl, alkanoyl, aminocarbonyl, monoalkylaminocarbonyl, dialkylaminocarbonyl, alkyl amido, preferably lower alkyl amido, alkoxyalkyl, preferably a lower alkoxy[lower]alkyl, alkoxycarbonyl, preferably a lower alkoxycarbonyl, alkylcarbonyloxy, preferably a lower alkylcarbonyloxy, and aryl, preferably phenyl, said aryl being optionally substituted by halo, lower alkyl and lower alkoxy groups; wherein lower alkyl refers to unsubstituted alkyl groups of 1 to 4 carbon atoms. 
pri čemu su supstituenti za cikloalkenil i karbociklički prsten alkil, poželjno niži alkil, alkoksi, poželjno niži alkoksi, nitro, monoalkilamino, poželjno niži alkilamino, dialkilamino, poželjno di(niži)alkilamino, cijano, halo, haloalkil, poželjno trifluormetil, alkanoil, aminokarbonil, monoalkilaminokarbonil, dialkilaminokarbonil, alkilamido, poželjno niži alkilamido, alkoksialkil, poželjno niži alkoksi(niži)alkil, alkoksikarbonil, poželjno niži alkoksikarbonil, alkilkarboniloksi, poželjno niži alkilkarboniloksi, i aril, poželjno fenil, navedeni je aril prema izboru supstituiran s halo, nižim alkilnim i nižim alkoksi grupama; pri čemu se niži alkil odnosi na nesupstituirane alkilne grupe s 1 do 4 atoma ugljika.
wherein substituents for alkyl, alkylcarbonyl, alkylidene, cycloalkyl, amide, sulfonamido, sulfonamide, carbamate, aryl, alkenyl, alkynyl, heterocycle, heterocyclic ring, cycloalkenyl, carbocyclic ring are as defined in claim 1; 
pri čemu su supstituenti za alkil, alkilkarbonil, alkiliden, cikloalkil, amid, sulfonamido, sulfonamid, karbamat, aril, alkenil, alkinil, heterocikl, heterociklički prsten, cikloalkenil, karbociklički prsten kao definirani u patentnom zahtjevu 1;
is hydrogen, alkyl, substituted alkyl, amide, substituted amide, cycloalkyl or substituted cycloalkyl; 
je vodik, halogen, alkil, supstituirani alkil, amid, supstituirani amid, cikloalkil ili supstituirani cikloalkil;
is hydrogen, lower alkyl or substituted lower alkyl; 
je vodik, niži alkil ili supstituirani niži alkil;
wherein lower alkyl refers to unsubstituted alkyl groups of 1 to 4 carbon atoms. 
pri čemu se niži alkil odnosi na nesupstituirane alkilne grupe s 1 do 4 atoma ugljika.
A compound according to Claim 5 or 7 comprising: 
Tvar u skladu s patentnim zahtjevom 5 ili 7 sadrži:
A pharmaceutical composition comprising a pharmaceutically acceptable carrier and one or more compounds according to claims 1 to 8. 
Farmaceutski sastav sadrži farmaceutski prihvatljivi nosač i jednu ili više tvari u skladu s patentnim zahtjevima 1 do 8.
A compound for a use according to claim 11 wherein the proliferative disease is cancer. 
Tvar za uporabu u skladu s patentnim zahtjevom 11 gdje je proliferativna bolest rak.
A compound for a use according to claim 12 wherein the cancer is selected from the group consisting of carcinoma of the prostate, pancreatic ductal adreno-carcinoma, breast, colon, lung, ovary, pancreas and thyroid, neuroblastoma, glioblastoma, medulloblastoma and melanoma, multiple myeloma, and acute myelogenous leukemia (AML). 
Tvar za uporabu u skladu s patentnim zahtjevom 12 pri čemu je rak odabran iz grupe koja se sastoji od karcinoma prostate, duktalnog adrenokarcinoma gušterače, dojke, kolona, pluća, jajnika, gušterače i štitne žlijezde, neuroblastoma, glioblastoma, meduloblastoma i melanoma, multiplog mijeloma i akutne mijeloične leukemije (AML).
A compound for a use according to claim 15 wherein said protein tyrosine kinase is selected from the group consisting of one or more CDK2/cyclin E, Flt-3, Fak, GSK-3β, IGF-1R, IR, JAK2, Kit, Lck, Met, PDGFRβ, PKCa, Src, TrkA, TrkB, VEGFR-1,VEGFR-2 and VEGFR-3. 
Tvar za uporabu u skladu s patentnim zahtjevom 15 pri čemu je navedena proteinska tirozin kinaza odabrana iz grupe koja se sastoji od jedne ili više CDK2/ciklin E, Flt-3, Fak, GSK-3β, IGF-1R, IR, JAK2, Kit, Lck, Met, PDGFRβ, PKCa, Src, TrkA, TrkB, VEGFR-1, VEGFR-2 i VEGFR-3.
A compound for a use according to claim 18 wherein the PK related disorder is an IGF-1R related disorder selected from the group consisting of cancer, diabetes, an autoimmune disease, a hyperproliferation disorder, aging, acromegaly and Crohn's disease. 
Tvar za uporabu u skladu s patentnim zahtjevom 18 pri čemu je poremećaj povezan s PK poremećaj povezan s IGF-1R odabran iz grupe koja se sastoji od raka, dijabetesa, autoimune bolesti, hiperproliferacijskih poremećaja, starenja, akromegalije i Chronove bolesti.
A compound for a use according to claim 19 wherein the cancer is selected from the group consisting of carcinoma of the prostate, pancreatic ductal adreno-carcinoma, breast, colon, lung, ovary, pancreas and thyroid, neuroblastoma, glioblastoma, medulloblastoma, melanoma, multiple myeloma and acute myelogenous leukemia (AML). 
Tvar za uporabu u skladu s patentnim zahtjevom 19 pri čemu je rak odabran iz grupe koja se sastoji od karcinoma prostate, duktalnog adrenokarcinoma gušterače, dojke, kolona, pluća, jajnika, gušterače i štitne žlijezde, neuroblastoma, glioblastoma, meduloblastoma, melanoma, multiplog mijeloma i akutne mijeloične leukemije (AML).
A structure as claimed in claim 6, characterized in that each of said shaped slots (12) is longitudinally elongated and substantially symmetrical with respect of a transverse axis (X) with end portions (12", 12"') tapered in opposite directions to allow upturned positioning of the respective post (2, 2', 2", 2"'). 
Struktura prema patentnom zahtjevu 6, karakterizirana time što je svaki od navedenih oblikovanih utora (12) uzdužno produljen i sadržajno simetričan u odnosu na poprečnu os (X) s krajnjim dijelovima (12'', 12''') zašiljenim u suprotnim smjerovima za omogućavanje preokrenutog postavljanja odgovarajućeg podupirača (2, 2', 2'', 2''').
said composition formulated for transmucosal sublingual, buccal or nasal dosage. 
pri čemu je navedena kompozicija formulirana za transmukozalnu subligvalnu, bukalnu ili nazalnu dozu.
A composition according to claim 6, said triglyceride comprising a minimum of 95 per cent of saturated fatty acids with 8 and 10 carbon atoms. 
Kompozicija prema patentnom zahtjevu 6, naznačena time što navedeni triglicerid sadrži minimalno 95 postotaka zasićenih masnih kiselina sa 8 i 10 atoma ugljika.
A medicament delivery device containing a composition according to any preceding claim, said device adapted to deliver individual or successive doses of said composition, each individual or successive dose having a volume of less than 1000 microlitres. 
Uređaj za primjenu lijeka naznačen time što sadrži kompoziciju prema bilo kojem prethodnom patentnom zahtjevu, pri čemu je navedeni uređaj prilagođen za primjenu pojedinačnih ili uzastopnih doza navedene kompozicije, pri čemu svaka pojedinačna ili uzastopna doza ima volumenu manji od 1000 mikrolitara.
A medicament delivery device containing a composition according to any one of claims 1 to 9, said device adapted to deliver individual or successive doses of said composition, each individual or successive dose containing no more than 80mg of artemether or arteether, preferably no more than 10mg of artemether or arteether. 
Uređaj za primjenu lijeka naznačen time što sadrži kompoziciju prema bilo kojem od patentnih zahtjeva 1 do 9, pri čemu je navedeni uređaj prilagođen za primjenu pojedinačnih ili uzastopnih doza navedene kompozicije, pri čemu pojedinačna ili uzastopna doza sadrži ne više od 80 mg artemetra ili arteetra, poželjno ne više od 10 mg artmemetra ili arteetra.
A delivery device according to claim 10 or 11 wherein said device comprises a pump spray, preferably wherein said device is adapted to produce a spray of composition having a mean droplet diameter greater than 20 microns. 
Uređaj za primjenu prema patentnom zahtjevu 10 ili 11 naznačen time što navedeni uređaj sadrži sprej pumpu, poželjno gdje je navedeni uređaj prilagođen da proizvodi sprej od kompozicije koji ima prosječni dijametar kapljice veći od 20 mikrona.
An AAV vector comprising a gene of interest for use in a method for delivering said gene of interest to motor neurons or glial cells by intraperitoneal (i.p. 
AAV vektor koji sadrži gen od interesa za uporabu u metodi za dostavu navedenog gena od interesa motoričkim neuronima ili glija stanicama intraperitonealnim (i.p.
injection, preferably intravenous injection, of said AAV vector to a subject, wherein said AAV vector is: 
injiciranjem, poželjno intravenskim injiciranjem, navedenog AAV vektora subjektu, pri čemu je navedeni AAV vektor:
An AAV vector comprising a gene of interest for use in a method for delivering said gene of interest to the spinal cord by by intraperitoneal (i.p. 
AAV vektor koji sadrži gen od interesa za uporabu u metodi za dostavu navedenog gena od interesa kralježničnoj moždini intraperitonealnim (i.p.
a double-stranded self-complementary AAV9 vector, or 
dvolančani samokomplementarni AAV9 vektor, ili
An AAV vector comprising a therapeutic gene for use in a method for treating a motor neuron disorder in a subject, wherein said AAV vector is administered by by intraperitoneal (i.p. 
AAV vektor koji sadrži terapijski gen za uporabu u metodi za liječenje poremećaja motoričkih neurona u subjekta, pri čemu se navedeni AAV vektor daje intraperitonealnim (i.p.
injection, preferably intravenous injection, to said subject, said administration causing infection of motor neurons or glial cells and expression of the gene in motor neurons or glial cells, wherein said AAV vector is: 
injiciranjem, poželjno intravenskim injiciranjem, navedenom subjektu, navedena primjena uzrokuje infekciju motoričkih neurona ili glija stanica i ekspresiju gena u motoričkim neuronima ili glija stanicama, pri čemu je navedeni AAV vektor:
injection, preferably intravenous injection, of said vector, wherein said AAV vector is: 
injiciranjem, poželjno intravenskim injiciranjem, navedenog vektora, pri čemu je navedeni AAV vektor:
The AAV vector of any one of claims 1 to 4, wherein the AAV vector is an AAV2/9 vector comprising an AAV2-derived genome in an AAV9-derived capsid. 
AAV vektor iz bilo kojeg od patentnih zahtjeva 1 do 4, pri čemu je AAV vektor AAV2/9 vektor koji sadrži AAV2-derivirani genom u AAV9-deriviranoj kapsidi.
The AAV vector of any one of claims 1 to 5, wherein the AAV vector comprises a replication defective AAV genome lacking functional Rep and Cap coding viral sequences. 
AAV vektor iz bilo kojeg od patentnih zahtjeva 1 do 5, pri čemu AAV vektor obuhvaća replikacijom nedostatan AAV genom bez funkcionalnih Rep i Cap kodirajućih virusnih sljedova.
The AAV vector of claim 3 or claims 4 to 7 for their part depending on claim 3, wherein the disorder is selected from neurodegenerative diseases, neuromuscular diseases, pain, lysosomal diseases, trauma, bone marrow injuries, cancers of the nervous system, demyelinating diseases, autoimmune diseases of the nervous system, neurotoxic syndromes, sleeping disorders. 
AAV vektor iz patentnog zahtjeva 3 ili patentnih zahtjeva 4 do 7 za njihov dio ovisan o patentnom zahtjevu 3, pri čemu je poremećaj odabran između neurodegenerativnih bolesti, neuromuskularnih bolesti, boli, lizosomskih bolesti, traume, ozljeda koštane srži, karcinoma živčanog sustava, demijelinizirajućih bolesti, autoimunih bolesti živčanog sustava, neurotoksičnih sindroma, poremećaja spavanja.
The AAV vector of any one of the preceding claims, wherein expression of the therapeutic protein is controlled by an ubiquitous, regulated and/or tissue-specific promoter. 
AAV vektor iz bilo kojeg od prethodnih patentnih zahtjeva, pri čemu je ekspresija terapijskog proteina kontrolirana sveprisutnim, reguliranim i/ili tkivno-specifičnim promotorom.
The AAV vector of claim 8, wherein the gene encodes the SMN protein and the disorder is spinal muscular atrophy (SMA). 
AAV vektor iz patentnog zahtjeva 8, pri čemu gen kodira SMN protein i poremećaj je spinalna mišićna atrofija (SMA).
is selected from the group consisting of H, OH, OCH3, and OCH2CH3; 
je odabran iz grupe koja se sastoji od H, OH, OCH3 i OCH2CH3;
The compound of claim 1 having the structure wherein B is selected from the group consisting of 
Tvar iz patentnog zahtjeva 1 ima strukturu [image] gdje je B odabran iz grupe koja se sastoji od [image]
The compound as recited in any one or more of the previous claims, wherein said compound consists essentially of a single stereoisomer. 
Tvar kako je nabrojena u jednom ili više od prethodnih patentnih zahtjeva, pri čemu se navedena tvar sastoji u osnovi od pojedinačnog stereoizomera.
The compound as recited in any one or more of claims 1 to 5, wherein said compound is a mixture of at least two diastereomers, a first diastereomer and a second diastereomer; wherein said first and second diastereomers are otherwise identical, except that said first and second diastereomers have different stereochemical configurations at a chiral phosphorus atom; wherein said chiral phosphorus atom is a phosphorus atom that is bound to a sulfur atom. 
Tvar kako je nabrojena u jednom ili više od patentnih zahtjeva 1 do 5, pri čemu je navedena tvar smjesa najmanje dva dijastereoizomera, prvi dijastereoizomer i drugi dijastereoizomer; pri čemu su navedeni prvi i navedeni drugi dijastereoizomeri inače identični, osim što navedeni prvi i drugi dijastereoizomeri imaju različite stereokemijske konfiguracije na kiralnom atomu fosfora; pri čemu je navedeni kiralni atom fosfora atom koji je vezan na atom sumpora.
An RNA molecule whose 5' end incorporates a compound as recited in any one or more of claims 1 to 5. 
Molekula RNA čiji 5' kraj ugrađuje tvar kako je nabrojena u jednom ili više patentnih zahtjeva 1 do 5.
A method for synthesizing a protein or peptide in vitro, said method comprising translating an RNA molecule as recited in claim 8 in a cell-free protein synthesis system, wherein the RNA molecule comprises an open reading frame, under conditions conducive to translating the open reading frame of the RNA molecule into the protein or peptide encoded by the open reading frame. 
Metoda za in vitro sintetiziranje proteina ili peptida, navedena metoda sadrži translaciju molekule RNA nabrojene u patentnom zahtjevu 8 u sustavu sinteze proteina bez stanice, pri čemu molekula RNA sadrži otvoreni okvir čitanja, pod uvjetima povoljnim za translaciju otvorenog okvira čitanja molekule RNA u protein ili peptid kodiran otvorenim okvirom čitanja.
A method for synthesizing a protein or peptide in vivo, said method comprising introducing an RNA molecule as recited in claim 8 into cells, wherein the RNA molecule comprises an open reading frame, under conditions conducive to translating the open reading frame of the RNA molecule into the protein or peptide encoded by the open reading frame. 
Metoda za sintetiziranje proteina ili peptida in vitro, navedena metoda sadrži uvođenje molekule RNA nabrojene u patentnom zahtjevu 8 u stanice, pri čemu molekula RNA sadrži otvoreni okvir čitanja, pod uvjetima povoljnim za translaciju otvorenog okvira čitanja molekule RNA u protein ili peptid kodiran otvorenim okvirom čitanja.
The pharmaceutical composition according to claim 1 wherein the compound of formula (I) has the structure: 
Kombinacija prema patentnom zahtjevu 1 pri čemu spoj formule (I) ima strukturu:
and R2 are independently chosen from hydrogen, C1-6 alkyl, and substituted C1-6 alkyl; 
i R2 su neovisno odabrani od vodika, C1-6 alkila i supstituiranog C1-6 alkila;
or R3 and R4 together with the nitrogen to which they are bonded form a ring chosen from a C5-10 heteroaryl, substituted C5-10 heteroaryl, C5-10 heterocycloalkyl, and substituted C5-10 heterocycloalkyl; and 
ili R3 i R4 zajedno s dušikom na kojega su vezani, tvore prsten odabran od sljedećih: C5-10heteroaril, supstituirani C5-10 heteroaril, C5-10 heterocikloalkil i supstituirani C5-10 heterocikloalkil; i
A compound according to claim 1, wherein R3 and R4 together with the nitrogen to which they are bonded form a C5-10 heterocycloalkyl ring. 
Spoj prema zahtjevu 1, naznačen time, da R3 i R4 zajedno s dušikom na kojega su vezani, tvore C5-10 heterocikloalkil-prsten.
A compound according to claim 1, wherein R3 and R4 together with the nitrogen to which they are bonded form a ring chosen from piperazine, 1,3-oxazolidinyl, pyrolidine, and morpholine ring. 
Spoj prema zahtjevu 1, naznačen time, da R3 i R4 zajedno s dušikom na kojega su vezani, tvore prsten odabran od piperazina, 1,3-oksazolidinila, pirolidina i morfolin-prstena.
A compound according to claim 1, wherein each of R1 and R2 is hydrogen; and R3 and R4 together with the nitrogen to which they are bonded form a ring chosen from a C5-6 heterocycloalkyl, substituted C5-6 heterocycloalkyl, C5-6 heteroaryl, and substituted C5-6 heteroaryl ring. 
Spoj prema zahtjevu 1, naznačen time, da je svaki od R1 i R2 vodik; a R3 i R4 zajedno s dušikom na kojega su vezani, tvore prsten odabran od sljedećih: C5-6 heterocikloalkil, supstituirani C5-6 heterocikloalkil, C5-6 heteroaril i supstituirani C5-6 heteroaril-prsten,
A pharmaceutical composition according to claim 23, which is an oral formulation. 
Farmaceutski sastav prema zahtjevu 23, naznačen time, da je to oralna formulacija.
A pharmaceutical composition according to claim 23, which is an oral controlled release formulation. 
Farmaceutski sastav prema zahtjevu 23, naznačen time, da je to oralna formulacija koja ima kontrolirano otpuštanje.
A pharmaceutical composition according to claim 23, which is an oral sustained release formulation. 
Farmaceutski sastav prema zahtjevu 23, naznačen time, da je to oralna formulacija koja ima kontinuirano otpuštanje.
A pharmaceutical composition according to any one of claims 23 to 26, further comprising another therapeutic agent. 
Farmaceutski sastav prema bilo kojem zahtjevu od 23 do 26, naznačen time, da nadalje obuhvaća jedno dodatno terapeutsko sredstvo.
A pharmaceutical composition according to claim 27, wherein the other therapeutic agent is effective in minimizing an adverse effect associated with the compound. 
Farmaceutski sastav prema zahtjevu 27, naznačen time, da jedno dodatno terapeutsko sredstvo je djelotvorno za minimaliziranje nepovoljnog djelovanja koje je povezano sa spojem.
A compound according to any one of claims 1 to 22 or a pharmaceutical composition according to any one of claims 23 to 28 for use in treatment of psoriasis, multiple sclerosis, an inflammatory bowel disease, asthma, chronic obstructive pulmonary disease, or arthritis. 
Spoj prema bilo kojem zahtjevu od 1 do 22 ili farmaceutski sastav prema bilo kojem zahtjevu od 23 do 28, naznačen time, da se upotrebljava u liječenju psorijaze, multiple skleroze, upalne bolesti crijeva, astme, kronične opstrukcijske plućne bolesti ili artritisa.
A compound according to any one of claims 1 to 22 or a pharmaceutical composition according to any one of claims 23 to 28 for use in treatment of psoriasis, asthma, chronic obstructive pulmonary disease, cardiac insufficiency, left ventricular insufficiency, myocardial infarction, angina pectoris, Parkinson's disease, Alzheimer's disease, Huntington's disease, retinopathia pigmentosa, mitochondrial encephalomyopathy, transplantation rejection, multiple sclerosis, ischemia, reperfusion injury, AGE-induced genome damage, inflammatory bowel disease, Crohn's disease, or ulcerative colitis. 
Spoj prema bilo kojem zahtjevu od 1 do 22 ili farmaceutski sastav prema bilo kojem zahtjevu od 23 do 28, naznačen time, da se upotrebljava u liječenju psorijaze, astme, kronične opstrukcijske plućne bolesti, kardijske insuficijencije, lijeve ventrikularne insuficijencije, infarkta miokarda, angine pektoris, Parkinsonove bolesti, Alzheimerove bolesti, Huntingtonove bolesti, pigmentozne retinopatije, mitohondrijske encefalomiopatije, odbijanja transplantata, multiple skleroze, ishemije, reperfuzijske ozljede, AGE-induciranog genomskog oštećenja, upalne bolesti crijeva, Crohnove bolesti ili ulcerativnog kolitisa.